Vendor Intelligence Report: Heman Peptide HM
Published 12 Nov 2026. 38-page investigative report on who is behind Heman Peptide HM: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.
Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.
Executive summary
Heman Peptide HM is not a throwaway storefront, but it is not a simple vendor to authenticate. The report finds a renewed China-linked domain, GLP1 Forum sponsorship, vendor-submitted Janoshik testing signals, and a meaningful Finnrick lab record. The same record also points to unresolved ownership, agent-mediated sales, weak official verification controls, and an active copycat/search-diversion environment around the brand.
Across 172 Finnrick lab tests, Heman’s supplied record is 127 pass / 44 fail, an overall pass rate of 74%. The useful signal is product-specific: GHK-Cu and Retatrutide are strongest-supported choices, while NAD+, KPV, MOTS-c and CJC-1295 sit in the fail-heavy tail. Ratings also compress under stricter purity/fill grading, so the full breakdown matters for dose-sensitive buyers.
Beyond the lab record, the investigation follows Heman’s corporate and channel trail. Heman’s own pages point to a Hebei sanitary-products company, while a second peptide storefront shares that company’s QQ email and Heman pages carry an HK Peptide | Official Website title string despite HK Peptide’s no-affiliate warning. The report distinguishes those operator-network leads from what remains unproven: ultimate ownership, a peptide facility, and the public batch-release chain.
The buyer-critical finding is diversion risk. Multiple Heman-branded lookalikes reuse logo assets, copied text or byte-identical contact pages, with clone rails including Zelle, CashApp, Chime and crypto. A parasite-SEO network and cloaked WhatsApp funnel further contaminate brand search, making manual channel verification and current-lot evidence central to any Heman order.
Inside the full report:
- Per-product pass/fail rates, rating trajectories and methodology-divergence charts for all 15 tested products
- Corporate identity analysis of Hebei Wangman, HK Peptide/Kuisu leads and the Meirong shared-email link
- Domain and infrastructure records for the official site plus Heman-branded lookalikes
- Clone-site evidence including reused logo artwork, byte-identical contact pages and payment rails
- Forum, Reddit and agent-channel review including the Mia Kuang non-fulfilment allegation and EU-warehouse signal
- Parasite-SEO and cloaked WhatsApp funnel analysis around Heman search terms
Risk assessment
- Impersonation / clone-site diversion risk — high: Five Heman-branded lookalike domains were identified; active clones reuse Heman assets/copy and push irreversible payment rails while the official site lacks strong verification controls.
- Agent-mediated payment and channel-authenticity risk — high: Orders route through WhatsApp agents with no official roster; the public Mia Kuang $3,000 non-fulfilment allegation remains unresolved and agent changes create authentication risk.
- Product-specific quality risk on weak Heman products — high: Finnrick rates NAD+ 19.89%, KPV 21.81%, MOTS-c 30.48%, CJC-1295 33.74%, TB-500 43.45% and Glutathione 49.99%; these products should not be scaled through Heman without fresh independent verification.
- Corporate-accountability opacity risk — high: The public record ties Heman to Hebei Wangman, HK Peptide/Kuisu leads and Meirong, but no UBO, payment-facing legal entity, batch-release officer or peptide facility is verified.
- Affiliate-promotion and search-funnel risk — medium: Dozens of parasite-SEO pages and a cloaked WhatsApp funnel target Heman search terms; no evidence Heman commissioned them, but buyers relying on search/review pages face misrouting.